Forbes

A Higher Calling

Billionair­e BEAU WRIGLEY is building his cannabis company, PARALLEL , to be bigger than his family’s chewing gum business—and he’s not banking on getting consumers stoned.

- By Will Yakowicz

Billionair­e Beau Wrigley is building his cannabis firm to be bigger than his family’s chewing gum business— and not by getting people stoned.

I2017, when billionair­e William “Beau” Wrigley Jr. was pitched cannabis as a new investment opportunit­y by his family office’s managing director, Jay Holmes, he shut it down immediatel­y. “Are you kidding me?” he said. “I’m not excited about wearing orange and possibly ending up in prison.”

Still, Wrigley, heir to the all-American chewing gum fortune, couldn’t deny that the burgeoning legal marijuana industry checked off all his investment criteria: a trend in changing consumer behavior, a transformi­ng regulatory environmen­t and multiple applicatio­ns in health care.

So Wrigley rethought the propositio­n. He told Holmes to find a target company, and he eventually located one at home in Florida: Surterra Wellness. Wrigley and his team flew down to its 180,000-square-foot operation outside Tampa, the company’s biggest facility where cannabis flower is

grown. After inspecting the cultivatio­n site—it was the first time the 57-year-old Wrigley, who says he has smoked pot only once in his life, had seen a room full of cannabis—the group boarded the plane home with the flowers’ sweet, pungent smell permeating their clothing.

“No one had known where we were, and I think they thought we were out getting high,” Wrigley recalls on a sunny afternoon while sitting on the patio of his North Palm Beach estate on Lake Worth lagoon.

Soon after that excursion, he led a $65 million investment round in Surterra, and in November 2018, he replaced the company’s cofounder as CEO. Renamed Parallel, Wrigley’s company now has 42 dispensari­es across three states, with 39 in Florida and the rest in Massachuse­tts and Nevada, with new ones slated to open in Pennsylvan­ia and Texas. To date, it has raised a total of $400 million largely from Wrigley and other high-net-worth individual­s. The latest funding round, which closed in 2020, valued the $250 million company (2020 sales) at an estimated $2 billion.

In 2019, Parallel spent more than $100 million on a Boston-based startup, Molecular Infusions, which is working on a THC-infused seltzer. Parallel is also in talks for a roughly $150 million acquisitio­n of a three-store dispensary chain in Chicago, which would bring the company to the city synonymous with the Wrigley name.

It’s also exploring going public in Canada via a SPAC deal, according to two people with knowledge of the discussion­s. Wrigley denies that the company will go public.

In just three years, Wrigley has transforme­d Parallel into a new kind of cannabis company. On a mission to build the first mainstream marijuana brand, he has stacked his management with executives and advisors from some of the largest and best-known corporatio­ns in the world—including Coca-Cola, Walgreens and Patrón Spirits. Wrigley believes his cannabis concern could one day rival his family’s chewing gum business, which he sold to Mars, Inc. for $23 billion in 2008.

“I think this can be bigger than the Wrigley company,” he says. “At Wrigley, we brought joy to people’s lives. This is much bigger than that.”

Parallel is not the largest cannabis firm in America—Massachuse­tts-based Curaleaf is—or even the largest in Florida (that’s Trulieve), but it has slowly and methodical­ly built up its operations. Its strategy is markedly different from that of Curaleaf, which pulled off an aggressive national rollup strategy headed by its billionair­e chairman, Boris Jordan. Instead of a national land grab, Wrigley has mostly focused on Florida, which he calls “New York South” and where medical marijuana is legal.

Florida has a growing population of 21 million and more than 100 million visitors every year, and Wrigley expects that when it legalizes cannabis for recreation­al use, his company will grow by a factor of ten. “The potential is huge in Florida alone,” he says.

The hidden value in Parallel lies in its investment­s in medical and recreation­al R&D. The company inked an exclusive partnershi­p with biopharma company Eleszto Genetika in Budapest, Hungary, in 2019. Through a yeast-based microbial process, Eleszto Genetika can geneticall­y sequence rare cannabinoi­ds and engineer specific effects at commercial scale. One future product

Wrigley is excited about is CBN, a cannabinoi­d that helps improve sleep.

“Call it an ‘Ambien killer,’ ” he says.

Parallel is also looking at THCV, which has the same euphoric effects as THC, the main psychoacti­ve compound in cannabis, but is an appetite suppressan­t—meaning no more “munchies,” he says. The idea is to create a noncaloric alcohol replacemen­t that “makes you feel better, is not more addictive than a cup of coffee, has no side effects,” he adds. “And, oh, by the way, it suppresses your appetite.”

He goes on, his Italian water dog, Rio, sitting at his feet: “One of these products is bigger than the entire company.”

Wrigley, who uses his company’s THC drops in lime LaCroix to unwind, says cannabinoi­ds have the potential to improve “quality of life,” whether by easing one’s pain, reducing anxiety or helping promote a good night’s rest.

Parallel also has something no other cannabis company has: the Wrigley name.

Morgan Paxhia, cofounder of a San Francisco– based $150 million cannabis investment firm, believes Wrigley is primed to build a successful, mainstream cannabis company. “It’s ingrained in their DNA,” Paxhia says. “Multigener­ation, family-driven—this is how we build big, durable legacy brands.”

Wrigley was born into one of America’s great business dynasties. His namesake great-grandfathe­r, William Wrigley Jr., started William Wrigley Co. in 1891 as a manufactur­er of soap but pivoted in 1893 to produce Wrigley’s chewing gum instead. The company was handed down through the generation­s, and Beau’s father ran it until the day he died, in March 1999. Beau, who started working at the company over his summer break when he was 13, was 35 years old when he became CEO and chairman the day after his father passed away.

He is credited with breathing life into a 100-year-old family business by helping replace its natural-gum formula with a more cost-effective synthetic base and expanding its reach by acquiring Life Savers and Altoids. In October 2008, Wrigley closed the deal of his lifetime—he took Wrigley Co. private by selling to Mars, Inc., another company owned by a family of billionair­es.

Understand­ably, many assume Wrigley will produce a cannabis gum one day. After launching into a three-minute explanatio­n of the science and molecular biology behind ensuring the release of the right flavors for the appropriat­e amount of time from chewing gum base, he says he’s concerned about how expensive the R&D process could be—as well as the risk of appealing to children. Still: “Never say never,” he says.

Much like Wrigley Co., Parallel has global ambitions. According to an investment document obtained by Forbes, Parallel is exploring cannabis and hemp cultivatio­n licenses in Southeast Asia. (Wrigley admits he has spoken to government officials in the region but says talks have slowed during the pandemic.)

“In comparison to Wrigley, this is also a crosscultu­ral product,” he says. “Just like we sold in 180 countries, cannabis plays everywhere.”

When asked what his ancestors would think about his foray into the industry, Wrigley takes his time to answer. Standing on a wooden walkway leading to the main entrance of his estate, he is flanked by two ponds filled with koi. Flags on a small putting green nearby wave in the breeze off Lake Worth.

“Gosh, at first blush they would roll over in their graves,” he says with a smile.

Although pot is still illegal under federal law, 43 states have created their own legal markets of one kind or another, and with Democrats now in control of Congress, national legalizati­on seems closer than ever. “I don’t consider our business illegal,” he says. “It’s caught up in a political quagmire for the moment.”

Wrigley, who has a net worth of $3.1 billion, says he feels lucky to be a part of helping an industry transform from black-market to legal. The last generation of entreprene­urs who made that claim turned the desert town of Las Vegas into a city home to multibilli­on-dollar public corporatio­ns. Wrigley compares the cannabis industry today to Vegas in the post-Mafia period before luxury hotels dominated the Strip.

“I see us [as] in the era before Steve Wynn came and made it a destinatio­n experience,” he says. “Anyone can put up a table with green felt and gamble. But he created this whole experienti­al thing with the art, the Bellagio, the fountains, and it became a destinatio­n.” Wrigley believes Parallel can become the world’s first gold-standard cannabis company by changing how Americans view marijuana, much like Wynn made over Sin City’s image. “It isn’t about getting high,” he says. “It’s about quality of life.”

FINAL THOUGHT “MR. WRIGLEY BELIEVED IN THIS: PUT ALL YOUR EGGS IN ONE BASKET AND WATCH THE BASKET.” —Ernie Banks

 ??  ?? Beau Knows
Part of Wrigley’s business motivation is to find replacemen­ts for Big Pharma drugs. He believes innovative cannabis products can “change the face of health care.”
Beau Knows Part of Wrigley’s business motivation is to find replacemen­ts for Big Pharma drugs. He believes innovative cannabis products can “change the face of health care.”
 ??  ?? Parallel Lines
Among Wrigley’s cannabis brands is Jimmy Buffett’s Coral Reefer, which includes
vapes, balms and gummies—but no gum.
Parallel Lines Among Wrigley’s cannabis brands is Jimmy Buffett’s Coral Reefer, which includes vapes, balms and gummies—but no gum.
 ??  ??
 ??  ??
 ??  ??

Newspapers in English

Newspapers from United States